Compare Boston Beer Company Inc (SAM) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs Sana Biotechnology Inc — how do they compare? Boston Beer Company Inc trades at $171.2 (market cap $1.76B), while Sana Biotechnology Inc trades at $2.77 (market cap $836.71M). The key difference: Boston Beer Company Inc is far larger — about 2.1× Sana Biotechnology Inc's market cap, and Boston Beer Company Inc is more actively traded (264,496 versus 4,507,444). Which is the better fit depends on your goals — on Pluang, investors hold Boston Beer Company Inc for 59 Days and Sana Biotechnology Inc for 23 Days on average.
| SAM | SANA | |
|---|---|---|
Market Cap | $1.76B | $836.71M |
Volume | 264,496 | 4,507,444 |
Sector | Consumer Staples | Health |
52-Week High | $260.05 | $5.92 |
52-Week Low | $161.08 | $2.68 |
Typical Hold Time | 59 Days | 23 Days |
Enterprise Value | $1.53B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SAM trades at $168.16, down 1.3% over the past day, with a neutral technical signal and bearish moving averages. The stock has a P/E of 22.66 and P/S of 0.94, indicating moderate valuation. Recent earnings missed expectations in Q1 and Q2 2026, but net income improved to $108.47M in 2025. The company is expanding its product portfolio with new cocktails and coolers, though volume growth remains a challenge.
The outlook is mixed: analyst consensus is a $204.44 price target with a majority hold rating, but negative net income margin and ROE highlight profitability risks. Key opportunities include brand investments and innovation, while risks involve declining volumes and cost pressures in a competitive market.
SANA Biotechnology trades at $2.72, down 1.09% with a bearish technical signal despite bullish oscillators. The company shows significant financial challenges with negative revenue, a net loss of $244.17 million in 2025, and negative cash flow. However, analyst sentiment remains positive with 82% buy ratings and recent conference presentations highlighting ongoing research in engineered cell therapies.
The outlook is highly speculative given the pre-revenue stage and substantial losses. Investment opportunity lies in the potential of SANA's biotechnology platform, but risks include cash burn, clinical trial outcomes, and competitive pressures. Wall Street maintains cautious optimism despite fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
